{
    "symbol": "LMNL",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-13 22:17:02",
    "content": " Research and development or R&D expenses from continuing operations decreased $1.5 million from $5 million in the comparative period to $3.5 million for the 3-month period ended September 30, 2022 due to decreases in intangible asset depreciation expense, royalty expenses and clinical trial costs of $0.4 million, $0.3 million and $0.2 million respectively and a general reduction in operating expenses. Admin expenses from continuing operations decreased $5 million from $9.4 million in the comparative period to $4.4 million during the current 3-month period ended September 30, 2022. Finance costs from continuing operations decreased by $2.8 million from $1.9 million in the comparative period compared to a $0.9 million gain for the quarter ended September 30, 2022. Net loss from continuing operations, net of taxes decreased by $5.2 million during the quarter ended September 30, 2022 compared to the corresponding period in 2021. Income from discontinued operations, net of taxes, decreased by $57.4 million during the quarter ended September 30, 2022 compared to the corresponding period in 2021."
}